We will characterize structural determinants of HIV-1 Vif, HIV-2 Vif, A3G, and A3F that interact and induce degradation of A3G and A3F. The determinants of HIV-1 Vif that interact with A3G and A3F are not conserved in HIV-2 Vif, suggesting that HIV-2 Vif induces A3 protein degradation using distinct interactions. We will carry out extensive mutational analysis of HIV-1 Vif, HIV-2 Vif, A3G, and A3F to identify structural determinants of each protein that interact with each other. We will also characterize determinants of A3G-A3G interactions in cells using bimolecular fluorescence complementation. We will develop small-molecule inhibitors of A3G-Vif and A3F-Vif interactions. We have developed in situ assays for high-throughput screening of small-molecule inhibitors that interfere with HIV-1 Vif-mediated degradation of A3G and A3F. In collaboration with the NIH Chemical Genomics Center, we will screen a library of >300,000 compounds to identify inhibitors of this novel target for antiviral drug development. We will also identify inhibitors of HIV-2 Vif and A3 interaction for the treatment of HIV-2 infection. We will determine the impact of A3G- and A3F-mediated hypermutation on the HIV-1 genome. To gain insight into the impact of hypermutation on viral evolution, we will carry out ultradeep sequencing analysis to identify and characterize the entire HIV-1 genome with respect to A3-mediated G-to-A hypermutation target sites to identify mutational hotspots and coldspots. We will identify the site of ubiquitination on A3F. We will quantify the antiviral activity of A3 proteins in primary CD4+ T cells and macrophages. We will determine the relative inhibitory potential of A3G and A3F in primary activated CD4+ T cells and macrophages using different modes of activation and cytokine stimulation to gain insights into their antiviral activity under various physiological conditions. We will analyze the role of A3 proteins in P bodies, and the mechanism by which Mov10 inhibits retroviral replication. We have observed that Mov10, an interferon-inducible P body protein, inhibits HIV-1 replication at the level of virus production and reverse transcription. To elucidate the mechanism of inhibition, we will analyze Mov10 virion incorporation and its effects on Gag expression and reverse transcription. To gain insights into the interactions of APOBEC3 proteins with viral components after infection, we will use live-cell imaging to determine the kinetics with which APOBEC3 proteins dissociate from the viral preintegration complexes. [Corresponds to Pathak Project 2 in the October 2011 site visit report of the HIV Drug Resistance Program]

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
1ZIABC010595-09
Application #
8552743
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
9
Fiscal Year
2012
Total Cost
$25,000
Indirect Cost
Name
National Cancer Institute Division of Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
Chen, Jianbo; Rahman, Sheikh Abdul; Nikolaitchik, Olga A et al. (2016) HIV-1 RNA genome dimerizes on the plasma membrane in the presence of Gag protein. Proc Natl Acad Sci U S A 113:E201-8
Delviks-Frankenberry, Krista A; Nikolaitchik, Olga A; Burdick, Ryan C et al. (2016) Minimal Contribution of APOBEC3-Induced G-to-A Hypermutation to HIV-1 Recombination and Genetic Variation. PLoS Pathog 12:e1005646
Sardo, Luca; Hatch, Steven C; Chen, Jianbo et al. (2015) Dynamics of HIV-1 RNA Near the Plasma Membrane during Virus Assembly. J Virol 89:10832-40
Chikaev, Anton N; Bakulina, Anastasiya Yu; Burdick, Ryan C et al. (2015) Selection of peptide mimics of HIV-1 epitope recognized by neutralizing antibody VRC01. PLoS One 10:e0120847
Smith, Jessica L; Izumi, Taisuke; Borbet, Timothy C et al. (2014) HIV-1 and HIV-2 Vif interact with human APOBEC3 proteins using completely different determinants. J Virol 88:9893-908
Sato, Kei; Takeuchi, Junko S; Misawa, Naoko et al. (2014) APOBEC3D and APOBEC3F potently promote HIV-1 diversification and evolution in humanized mouse model. PLoS Pathog 10:e1004453
Burdick, Ryan C; Hu, Wei-Shau; Pathak, Vinay K (2013) Nuclear import of APOBEC3F-labeled HIV-1 preintegration complexes. Proc Natl Acad Sci U S A 110:E4780-9
Chaipan, Chawaree; Smith, Jessica L; Hu, Wei-Shau et al. (2013) APOBEC3G restricts HIV-1 to a greater extent than APOBEC3F and APOBEC3DE in human primary CD4+ T cells and macrophages. J Virol 87:444-53
Izumi, Taisuke; Burdick, Ryan; Shigemi, Mayu et al. (2013) Mov10 and APOBEC3G localization to processing bodies is not required for virion incorporation and antiviral activity. J Virol 87:11047-62
Pak, Vladimir; Heidecker, Gisela; Pathak, Vinay K et al. (2011) The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B. J Virol 85:8538-47

Showing the most recent 10 out of 20 publications